Head-to-head evidence
Levodopa-carbidopa intestinal gel vs TR-012001
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
Levodopa-carbidopa intestinal gel · Duopa
Marketed by AbbVie
NCT00335153 · Phase 3 · completed
This was a 354-participant, open-label, single-group study with no randomization, blinding, or comparator arm. Its primary outcomes focused on safety and device complications, and there was no formal controlled primary efficacy comparison, so the reported secondary improvements do not establish treatment efficacy.
TR-012001
Developed by SNLD, Ltd.
NCT06212089 · Phase 2 · completed
The study randomly assigned 12 participants to TR-012001 or placebo and masked participants, but it was single-blind and very small. Because no results are posted, it cannot establish whether the primary safety comparisons were favorable or statistically significant.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Levodopa-carbidopa intestinal gel's landscape · TR-012001's landscape